281 related articles for article (PubMed ID: 30037800)
1. CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia.
Jiang YP; Liu BY; Zheng Q; Panuganti S; Chen R; Zhu J; Mishra M; Huang J; Dao-Pick T; Roy S; Zhao X; Lin J; Banik G; Hsi ED; Mandalam R; Junutula JR
Blood Adv; 2018 Jul; 2(14):1738-1749. PubMed ID: 30037800
[TBL] [Abstract][Full Text] [Related]
2. An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia.
Zheng B; Yu SF; Del Rosario G; Leong SR; Lee GY; Vij R; Chiu C; Liang WC; Wu Y; Chalouni C; Sadowsky J; Clark V; Hendricks A; Poon KA; Chu W; Pillow T; Schutten MM; Flygare J; Polson AG
Clin Cancer Res; 2019 Feb; 25(4):1358-1368. PubMed ID: 29959143
[TBL] [Abstract][Full Text] [Related]
3. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
[TBL] [Abstract][Full Text] [Related]
4. A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells.
Arvindam US; van Hauten PMM; Schirm D; Schaap N; Hobo W; Blazar BR; Vallera DA; Dolstra H; Felices M; Miller JS
Leukemia; 2021 Jun; 35(6):1586-1596. PubMed ID: 33097838
[TBL] [Abstract][Full Text] [Related]
5. Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes.
Yanagisawa B; Perkins B; Karantanos T; Levis M; Ghiaur G; Smith BD; Jones RJ
Leuk Res; 2020 Dec; 99():106477. PubMed ID: 33220589
[TBL] [Abstract][Full Text] [Related]
6. IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML.
Kovtun Y; Noordhuis P; Whiteman KR; Watkins K; Jones GE; Harvey L; Lai KC; Portwood S; Adams S; Sloss CM; Schuurhuis GJ; Ossenkoppele G; Wang ES; Pinkas J
Mol Cancer Ther; 2018 Jun; 17(6):1271-1279. PubMed ID: 29588393
[TBL] [Abstract][Full Text] [Related]
7. Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia.
Zhang CC; Yan Z; Pascual B; Jackson-Fisher A; Huang DS; Zong Q; Elliott M; Fan C; Huser N; Lee J; Sung M; Sapra P
Neoplasia; 2018 Jan; 20(1):1-11. PubMed ID: 29172076
[TBL] [Abstract][Full Text] [Related]
8. Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.
Han YC; Kahler J; Piché-Nicholas N; Hu W; Thibault S; Jiang F; Leal M; Katragadda M; Maderna A; Dushin R; Prashad N; Charati MB; Clark T; Tumey LN; Tan X; Giannakou A; Rosfjord E; Gerber HP; Tchistiakova L; Loganzo F; O'Donnell CJ; Sapra P
Clin Cancer Res; 2021 Jan; 27(2):622-631. PubMed ID: 33148666
[TBL] [Abstract][Full Text] [Related]
9. The collagen receptor uPARAP/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers.
Nielsen CF; van Putten SM; Lund IK; Melander MC; Nørregaard KS; Jürgensen HJ; Reckzeh K; Christensen KR; Ingvarsen SZ; Gårdsvoll H; Jensen KE; Hamerlik P; Engelholm LH; Behrendt N
Oncotarget; 2017 Jul; 8(27):44605-44624. PubMed ID: 28574834
[TBL] [Abstract][Full Text] [Related]
10. LILRB4-targeting Antibody-Drug Conjugates for the Treatment of Acute Myeloid Leukemia.
Anami Y; Deng M; Gui X; Yamaguchi A; Yamazaki CM; Zhang N; Zhang CC; An Z; Tsuchikama K
Mol Cancer Ther; 2020 Nov; 19(11):2330-2339. PubMed ID: 32879051
[TBL] [Abstract][Full Text] [Related]
11. Examination of CD302 as a potential therapeutic target for acute myeloid leukemia.
Lo TH; Abadir E; Gasiorowski RE; Kabani K; Ramesh M; Orellana D; Fromm PD; Kupresanin F; Newman E; Cunningham I; Hart DNJ; Silveira PA; Clark GJ
PLoS One; 2019; 14(5):e0216368. PubMed ID: 31075107
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia.
Morsink LM; Walter RB; Ossenkoppele GJ
Blood Rev; 2019 Mar; 34():26-33. PubMed ID: 30401586
[TBL] [Abstract][Full Text] [Related]
13. Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia.
Lu H; Zhou Q; Deshmukh V; Phull H; Ma J; Tardif V; Naik RR; Bouvard C; Zhang Y; Choi S; Lawson BR; Zhu S; Kim CH; Schultz PG
Angew Chem Int Ed Engl; 2014 Sep; 53(37):9841-5. PubMed ID: 25056598
[TBL] [Abstract][Full Text] [Related]
14. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia.
Wang J; Chen S; Xiao W; Li W; Wang L; Yang S; Wang W; Xu L; Liao S; Liu W; Wang Y; Liu N; Zhang J; Xia X; Kang T; Chen G; Cai X; Yang H; Zhang X; Lu Y; Zhou P
J Hematol Oncol; 2018 Jan; 11(1):7. PubMed ID: 29316944
[TBL] [Abstract][Full Text] [Related]
15. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells.
Kovtun Y; Jones GE; Adams S; Harvey L; Audette CA; Wilhelm A; Bai C; Rui L; Laleau R; Liu F; Ab O; Setiady Y; Yoder NC; Goldmacher VS; Chari RVJ; Pinkas J; Chittenden T
Blood Adv; 2018 Apr; 2(8):848-858. PubMed ID: 29661755
[TBL] [Abstract][Full Text] [Related]
16. Characterization of high-affinity peptides and their feasibility for use in nanotherapeutics targeting leukemia stem cells.
Zhang H; Luo J; Li Y; Henderson PT; Wang Y; Wachsmann-Hogiu S; Zhao W; Lam KS; Pan CX
Nanomedicine; 2012 Oct; 8(7):1116-24. PubMed ID: 22197725
[TBL] [Abstract][Full Text] [Related]
17. Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia.
Lin TY; Zhu Y; Li Y; Zhang H; Ma AH; Long Q; Keck J; Lam KS; Pan CX; Jonas BA
Nanomedicine; 2019 Aug; 20():102004. PubMed ID: 31055076
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD19 CAR T Cells That Secrete a Biparatopic Anti-CLEC12A Bridging Protein Have Potent Activity Against Highly Aggressive Acute Myeloid Leukemia
Rennert PD; Dufort FJ; Su L; Sanford T; Birt A; Wu L; Lobb RR; Ambrose C
Mol Cancer Ther; 2021 Oct; 20(10):2071-2081. PubMed ID: 34253594
[TBL] [Abstract][Full Text] [Related]
19. Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia.
Zhao X; Singh S; Pardoux C; Zhao J; Hsi ED; Abo A; Korver W
Haematologica; 2010 Jan; 95(1):71-8. PubMed ID: 19648166
[TBL] [Abstract][Full Text] [Related]
20. Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.
Han L; Jorgensen JL; Brooks C; Shi C; Zhang Q; Nogueras González GM; Cavazos A; Pan R; Mu H; Wang SA; Zhou J; Ai-Atrash G; Ciurea SO; Rettig M; DiPersio JF; Cortes J; Huang X; Kantarjian HM; Andreeff M; Ravandi F; Konopleva M
Clin Cancer Res; 2017 Jul; 23(13):3385-3395. PubMed ID: 28096272
[No Abstract] [Full Text] [Related]
[Next] [New Search]